Placeholder Banner

BIO Submits Amicus Brief in Sandoz Inc. v. Amgen Manufacutring Inc. and Amgen Manufacturing Ltd v. Sandoz Inc. (U.S. Supreme Court)

March 17, 2017

BIO submitted an amicus brief in Sandoz Inc. v. Amgen Inc. and Amgen Manufacturing Limited, as well as Amgen Inc. and Amgen Manufacturing Limited v. Sandoz Inc., at the Supreme Court of the United States.

As one of the leading proponents for the creation of a biosimilar approval pathway that also maintains incentives for innovation, BIO has a strong interest in the proper implementation of this statutory scheme by the courts.

Related Resources
15-1039-15-1195-bsac-Biotechnology-Innovation-Organization 0
15-1039-15-1195-bsac-Biotechnology-Innovation-Organization
BIO Amgen v. Sandoz Brief (SCOTUS)
Discover More
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…
BIO filed an amicus brief in the U.S. Court of Appeals for the Sixth Circuit, seeking the reversal of a lower court's ruling that would set aside the 2022 rescission of the Securities and Exchange Commission (SEC) 2020 Rule regulating proxy advisory…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on an important and recurring question concerning the framework for determining patent obviousness in patent litigation. BIO argues that courts, when considering whether…